In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

(2013) L N Eadie et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

(2012) A. Giannoudis et al.   BLOOD

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1

(2011) Marta Gromicho et al.   LEUKEMIA & LYMPHOMA

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

(2010) L Eadie et al.   LEUKEMIA

Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity

(2010) J R Engler et al.   LEUKEMIA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

(2009) Edurne San José-Eneriz et al.   EUROPEAN JOURNAL OF CANCER

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

(2009) A Davies et al.   LEUKEMIA

Imatinib is a substrate for various multidrug resistance proteins

(2009) K. Czyzewski et al.   NEOPLASMA

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

(2008) A. Giannoudis et al.   BLOOD

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH

Part I: Milestones in personalised medicine—imatinib

(2008) Carlo Gambacorti-Passerini   LANCET ONCOLOGY

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy

(2007) Iman Jilani et al.   LEUKEMIA RESEARCH